ViiV and Janssen to test new HIV regimen in Phase III trial
January 7, 2016Manufacturing and Production, Medical Communications, Research and Development Edurant, HIV, Janssen, ViiV Healthcare, cabotegravir, collaboration, phase III, rilpivirine
Janssen has formalised its collaboration with ViiV Healthcare on the Phase III development and commercialisation of a two-drug regimen to …
PsiOxus Therapeutics appoints Dr Paolo Paoletti as chairman of the board
January 7, 2016Manufacturing and Production, Medical Communications, Research and Development Cancer, Dr Paolo Paoletti, GSK, PsiOxus Therapeutics, immuno-oncology, oncology
Immuno-oncology company PsiOxus Therapeutics has appointed Kesios Therapeutics chief executive, and former president of GSK Oncology, Dr Paolo Paoletti, as chairman …
Merck and Biocartis partner on new biomarker test for colorectal cancer
January 7, 2016Research and Development BRAF mutations, Diagnostics, Erbitux, Merck, RAS metations, diagnostic tests, metastic colorectal cancer
Merck has signed a collaboration agreement with diagnostics company Biocartis for the development and commercialisation of a new test for …
Janssen, Enterome and Kymab in research collaborations
January 7, 2016Research and Development Crohn's, Crohn’s disease, Enterome, Janssen, MD Anderson, alliance, antibodies, collaboration, crohn's disease, immuno-oncology, kymab, research
Several pharma companies have announced new collaborations, to research potential new drugs for Crohn’s disease, and immuno-oncology treatments for cancer. …
Terrence Higgins Trust announces new CEO
January 6, 2016Medical Communications AIDS, HIV, Terrance Higgins Trust
Leading UK-based HIV and sexual health charity The Terrence Higgins Trust has announced the appointment of Ian Green as the …
Gilead terminates Phase II simtuzumab IPF study
January 6, 2016Research and Development Gilead, IPF, idiopathic pulmonary fibrosis, simtuzumab
Gilead Sciences has announced the termination of its Phase II clinical study of the investigational monoclonal antibody simtuzumab in patients …
Trial launched to test exercise as prostate cancer treatment
January 6, 2016Research and Development Cancer Research UK, active surveillance, exercise, prostate cancer
Cancer Research UK has launched a study to determine if exercise could help men with prostate cancer, the UK’s most …
Dr Reddy’s relaunches generic Nexium in blue after AstraZeneca lawsuit
January 6, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Dr Reddy's, Nexium, acid reflux, esomeprazole, lawsuit, purple pill
Dr Reddy’s has relaunched its generic version of AstraZeneca’s blockbuster heartburn drug Nexium in the US, changing the colour from …
Valeant names interim CEO in Pearson’s absence
January 6, 2016Medical Communications, Sales and Marketing Valeant
Valeant has named company director Howard Schiller as interim chief executive officer to serve while full-time boss Michael Pearson is …
The case for adaptive trials in dementia
January 6, 2016Manufacturing and Production, Research and Development Alzheimer's, Alzheimer's disease, adaptive trials, research
An ageing population and widespread chronic neuro-degenerative disease will make dementia an ever increasing burden on society, families and the …
Roche teams with DH for drug repurposing trial
January 6, 2016Research and Development DH, NIHR, Off Patent Drugs Bill, Off-Patent Drugs Bill, RoActemra, Roche, drug repurposing, tocilizumab
Roche and the UK Department of Health have launched a trial, to explore whether one of the company’s treatments for …
Takeda and Enterome collaborate on new therapeutics for stomach disorders
January 6, 2016Research and Development Enterome, Takeda, gastrointestinal, inflammatory bowel syndrome, irritable bowel syndrome
Takeda and Enterome Bioscience have entered a drug discovery collaboration to research and develop potential new therapeutics for disorders including …
MSD chooses partner to develop ‘game-changing’ cancer therapies
January 6, 2016Research and Development CPABs, Cancer, Cell-Penetrating Alphabodies, Complix, MSD, autoimmune diseases
MSD has entered a research collaboration with biopharma company Complix, using the company’s proprietary technology to develop new treatments for …
Sanofi abandons MannKind’s failed inhalable insulin
January 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing Afrezza, Mannkind, Sanofi, insulin
Sanofi is to exit a licensing and co-marketing deal with MannKind for the inhalable insulin Afrezza, after disappointing sales figures …
Gilead success in late-stage hepatitis B trials
January 5, 2016Research and Development, Sales and Marketing Gilead, hepatitis B, phase III
Two Phase III trials evaluating Gilead treatments in chronic hepatitis B virus (HBV) infection have met their primary objectives, showing …
Eli Lilly predicts revenue growth in 2016
January 5, 2016Research and Development, Sales and Marketing Eli Lilly, financial reports, marketing, sales
Eli Lilly has set out its financial guidance for 2016, predicting an increase in sales to between $20.2 and $20.7 …
BioMarin elects former Allergan CEO to board
January 5, 2016Medical Communications, Research and Development, Sales and Marketing
BioMarin Pharmaceutical has announced the election of former Allergan chief executive, David Pyott, to the company’s board of directors. Pyott served …
Actelion’s Uptravi goes on sale
January 5, 2016Manufacturing and Production, Sales and Marketing Actelion, PAH, Uptravi, pulmonary arterial hypertension, pulmonary hypertension, selexipag
Swiss pharma firm Actelion has put its new drug for pulmonary hypertension, Uptravi, up for sale in the US, weeks …
Bayer and Baxalta in separate €1 billion-plus deals
January 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ascensia diabetes care, Baxalta, Bayer, diabetes, panasonic, symphogen
Baxalta has signed a deal with Symphogen potentially worth as much as €1.4 billion, under which the companies will develop …
Pfizer, Merck and Syndax in ovarian cancer trial collaboration
January 5, 2016Manufacturing and Production, Research and Development Merck, Pfizer, Syndax Pharmaceuticals, avelumab, entinostat, ovarian cancer
Pfizer, Merck and Syndax Pharmaceuticals have announced a collaboration to test avelumab, in combination with Syndax’s entinostat, in patients with …
Latest content
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
